The director of the U.S. Centers for Disease Control and Prevention (CDC), Rochelle Walensky, experienced a COVID-19 rebound after completing a course of Pfizer Inc's COVID-19 pill, the agency said on Monday.
Dr. Rochelle Walensky, director of Centers for Disease Control and Prevention answers questions during a Senate Health, Education, Labor, and Pensions Committee hearing to examine the federal response to the coronavirus disease and new emerging variants at Capitol Hill in Washington, D.C., U.S. January 11, 2022. Greg Nash/Pool via REUTERS/File Photo
Oct 31 - The director of the U.S. Centers for Disease Control and Prevention , Rochelle Walensky, experienced a COVID-19 rebound after completing a course of Pfizer Inc'sten days ago . After completing a course of Pfizer's Paxlovid, and a period of isolation, she had tested negative for the virus, but on Sunday, she tested positive again, CDC added.
Walensky is the third government executive, after U.S. President Joe Biden and National Institute of Allergy and Infectious Diseases Director Dr. Anthony Fauci, to experience a recurrent viral infection following the first course of Paxlovid. Some people who took the antiviral drug have suffered from a relapse or a rebound that occurred days after the five-day treatment course had
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Will Brazil’s COVID disaster sway its presidential election?President Jair Bolsonaro is up for re-election, but his policies failed to slow the coronavirus’s spread.
Read more »
As New COVID Variants Emerge at a Faster Pace, Here's What You Need to KnowDuring a coronavirus update Friday, Chicago’s top doctor said that new COVID variants are emerging “more quickly right now,” potentially marking a turning point in the pandemic as it enters its third winter.
Read more »
Scientists Fear New COVID Strains Are Deadly—Just Like 2020 WaveThe most recent COVID variants have been more contagious but less deadly. Early evidence suggests the new mutations could be much more dangerous and drive hospitalizations back up.
Read more »
Black patients suffered delays in COVID care after faulty readings by common device, study findsBlack patients experienced delays in COVID-19 treatment because a common medical device that measures blood oxygen levels tended to give inaccurate readings for darker-skinned individuals, accordin…
Read more »
Black patients suffered delays in COVID care after faulty readings by common device, study findsThe inaccurate measurements contributed to nearly five-hour delays in COVID-19 treatment, which was critical time for the potentially fatal virus, according to the study.
Read more »